Merck’s Hepatitis C Drug Works
FDA Grants Breakthrough Designations to Merck’s Hepatitis C Candidate
The FDA has granted 2 breakthrough therapy designations to Merck’s chronic hepatitis C virus (HCV) candidate, grazoprevir/elbasvir.
The once-daily, single-tablet regimen originally received breakthrough therapy status for the treatment of chronic HCV genotype 1 (GT1) infection in October 2013. However, the FDA rescinded it in January 2015.
Continue reading this entire article:
9 Foods to Restrain the Hepatitis C Virus
Phase III Trial Results for Ally-1 Reveal High HCV Cure Rates